

# Investor Presentation

Ascend

STRATEGY

February 20, 2025

Nasdaq: NDSN







# Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as "may," "will," "should," "could," "expects," "anticipates," "believes," "projects," "forecasts," "outlook," "guidance," "continue," "target," or the negative of these terms or comparable terminology. These statements reflect management's current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, U.S. and international economic conditions; financial and market conditions; currency exchange rates and devaluations; possible acquisitions, including the Company's ability to successfully integrate acquisitions; the Company's ability to successfully divest or dispose of businesses that are deemed not to fit with its strategic plan; the effects of changes in U.S. trade policy and trade agreements, including new or increased tariffs or trade restrictions; the effects of changes in tax law; and the possible effects of events beyond our control, such as political unrest, conflicts or wars between sovereign nations, acts of terror, natural disasters and pandemics, including the coronavirus (COVID-19) pandemic and the other factors discussed in Item 1A (Risk Factors) in the Company's most recently filed Annual Report on Form 10-K and in its Forms 10-Q filed with the Securities and Exchange Commission, which should be reviewed carefully. The Company undertakes no obligation to update or revise any forward-looking statement in this presentation.



Nordson is a growth compounder with unique competitive advantages

Company Founded 2024 Revenue 2024 EBITDA% Employees Countries with Direct Presence

1954

\$2.7B

32%

8,000+

35+





Consistent Record of Growth

Demonstrated Value to Customers

Disciplined focus on profitability

Solid Returns

Differentiated Product Portfolio\*

Consistent value to shareholders

6%

**Sales Growth** 

**55%** 

**Gross Margins** 

30%

**EBITDA Margins** 

13%

**ROIC** 

2,100+

Global Patents Held 61 yrs.

of Annual Dividend Increases



# Commitment to ESG





- 50% diverse board (3 gender and 2 racially or ethnically diverse)
- 9 out of 10 independent directors
- 6 years average tenure





- Nordson Impact Invest 5% of domestic pretax earnings in communities
- Paid time off for volunteer hours
- Employee support programs




**Environmental Stewardship** 

- Product design improvements focused on reducing customers' material utilization
- Journey to Zero adverse impacts to employees and community




## **Diversified Sources of Sales**

#### FY2024 Profile - \$2.7 Billion



High percentage of recurring sales from parts and consumables.




Diversified geographic footprint.

Direct presence in over

35 countries.



# **Diversified End Markets**



- Box sealing
- Baby diapers
- Convenience food packaging
- Beverage straw and spot attachment
- Container and bottle labeling

- Semiconductor packaging
- Wafer-level packaging
- Printed circuit boards
- Electronic component assembly – mobile phone, camera, ear buds, PC
- Automotive electronics

- Balloons, extrusions, delivery catheters and other minimally invasive devices
- Single-use fittings, connectors, fluid transfer components in medical equipment and surgical procedures
- Single-use specialty cannula for cardio-pulmonary procedures


- Construction and industrial machinery
- Rigid container
- Aerospace
- Chemical
- Defense
- Energy

- Consumer durable
- Automotive
- Animal health and delivery systems



# How We Are Organized





**INDUSTRIAL PRECISION SOLUTIONS** 

**MEDICAL FLUID SOLUTIONS** 

Adhesives, Industrial Coatings,
Measurement and Control Solutions & Polymer Processing Systems

Interventional Solutions, Fluid Components & Engineered Fluid Dispensing

Electronic Processing Systems & Test and Inspection

**55%**REVENUE

26% REVENUE

**19%** REVENUE



# Industrial Precision Solutions

2024 Revenue

\$1,399M

2024 Operating Margin\* 2024 EBITDA

34%

37%


#### What We Do

Product lines reduce material consumption, increase line efficiency, and enhance product brand and appearance. Components are used for dispensing adhesives, coatings, paint, finishes, sealants and other materials. This business primarily serves the industrial, consumer durables and non-durables markets.

#### **Long-Term Growth Driven By:**

- Material, machinery and process innovations
- Emerging markets and product tiering
- New applications, including electric vehicle battery, automotive electronics, and fabric bonding
- Recapitalization of large installed base





# Medical Fluid Solutions

2024 Revenues

\$695M

2024 Operating Margin\*

2024 EBITDA

29%

37%


#### What We Do

Fluid management solutions for medical, hightech industrial and other diverse end markets. Related plastic tubing, balloons, catheters, syringes, cartridges, tips, and fluid connection components are used to dispense or control fluids within customers' medical devices or products, as well as production processes.

#### **Long-Term Growth Driven By:**

- Aging population
- Trends toward non-invasive surgical techniques
- Medical OEM outsourcing
- Emerging markets





# Advanced Technology Solutions

#### What We Do

Design and develop proprietary technologies found in progressive stages of an electronics customer's production processes, such as surface treatment, precisely controlled dispensing of material and test, inspection and measurement to ensure quality and reliability.

#### Long-Term Growth Driven By:

- Electronics Broad solutions across the electronics supply chain
- 5G / Al / Big Data / Auto Electronics / Autonomous Vehicles / High-Perf Computing
- Emerging markets
- Deploying NBS Next in our divisions

2024 Revenues

\$696M

2024 Operating Margin\*

2024 EBITDA

19%

22%








# Why Invest in Nordson?

# A Growth Portfolio Ready to Accelerate



# 2025-2029 Financial Targets

Ascend STRATEGY

Revenue Growth

**Adjusted EPS** Growth

6-8% 10-12%

Average annual growth





# NBS Next

**GROWTH FRAMEWORK** 



Driving profitable growth by selecting and investing disproportionately in the best growth opportunities

# Owner Mindset

**DIVISION-LED** 

# Entrepreneurial division-led organization:

- Decisions close to the customer
- Autonomy + Accountability
- Clear line of sight to deploying NBS Next



# Winning Teams

TALENT STRATEGY

# A key ingredient to successful execution of the Ascend strategy:

- Leaders inspiring trust and building followership in the organization
- Focus on inclusion and diversity in everything we do
- Create an engaging culture that attracts and retains top talent



# Disciplined Approach to M&A



#### **Strategic Criteria**




#### **Financial Criteria**

- Serving attractive end market niches and applications
- Differentiated product technologies/solutions
- Additive to our growth focused portfolio

- Growth at or above market rates with Nordsonlike gross margins
- EBITDA ~20+% with margin expansion opportunities
- Returns that sufficiently exceed our cost of capital



# **Growth Algorithm**






# Superior Conversion / Deployment of Cash Flows

Generation of ~ \$4.1B in operating cash flows through 2029

#### Capital Deployment through 2029



#### **Cash Flow Deployment Priorities**

- Fund organic growth
- Return to shareholders thru dividends and routine stock repurchases to offset dilution
- Strategic deployment of ~\$2.8B for:
  - Strategic M&A
  - Debt service
  - Additional share repurchases





# Recent Financial Results

# Total Company – 1Q 2025




#### **Sales**

- Reported sales of \$615M, a decrease of 3%, at the low end of prior guidance range
- 8% growth from the Atrion acquisition; unfavorable currency impact of 2%
- 9% organic decrease driven by weakness in polymer processing, industrial coatings, electronics dispense, and select medical product lines

#### **EBITDA\***

- EBITDA was \$188 million, down 4% on lower sales volume
- Strong EBITDA margin of 31% in line with prior year





	1Q 2024	1Q 2025	$\Delta$
Sales	\$633.2	\$615.4	-3%
Operating Profit*	\$163.0	\$151.1	-7%
EBITDA*	\$196.5	\$188.1	-4%
EPS GAAP	\$1.90	\$1.65	-14%
EPS Adjusted*	\$2.21	\$2.06	-7%

<sup>\*</sup>Non-GAAP numbers - See appendix for reconciliation. In millions except for per share data.


#### Balance Sheet and Cash Flow



#### **Balanced Capital Deployment Returning Value to Shareholders**


#### **Net Debt**

- Cash totaled \$130 million
- 2.4x net debt leverage ratio based on trailing 12-month EBITDA, a reduction from prior quarter



#### Free Cash Flow\*

- Cash flow of \$138 million, which is a conversion rate of 146% of net income, deployed toward:
  - Share repurchases of \$60M
  - Dividend payments of \$45M
  - Capital investments of \$21M



<sup>\*</sup>Non-GAAP number – See appendix for reconciliation.


#### 2Q Fiscal 2025 Guidance



#### Steady performance moving into 2Q

- Historical seasonality and order entry trends support moderate increases in sales and earnings sequentially
- Backlog grew by ~\$85 million or 15% in the first quarter, ending at approximately \$670 million
- Order entry progressively improved throughout the quarter across all segments

Maintaining full-year guidance ranges, with sales expected to be toward the low end



#### 2025 Fiscal Full-Year Guidance



#### **Full-Year Growth from Record 2024**

- Ascend strategy is advancing and delivering results
- Backlog, including Atrion, is ~\$670 million as of 1/31/25
- Fiscal 2025 sales growth of 2% to 7%, inclusive of FX headwind of (1.5)%
- Adjusted earnings in the range of neutral to 8% growth
- For modeling purposes, consider:

	FY2025 Range
Effective tax rate	19-21%
Cap-ex	\$50-60 million
Interest	\$95-\$105 million




## Appendix 1:


# Product Innovation

# Our Electronics Industry Position

#### **Surface Mount Manufacturing**




#### QA Lab / Island of Automation






# Our Role in the Semiconductor Process





# CyberOptics expands market opportunities





3D Optical semi market expected to grow ~15%+, exceeding the broader 'Wafer Fab Equipment' market LSD '23 – '25 growth

# Medical and Fluid Solutions




From benchtop dispensers to industry-best jetting valves and automated dispensing robots, Nordson fluid solutions systems deliver accurate, repeatable deposits of glues, greases, and other industrial fluids in precise, low-volume applications.


From specialty tubing, catheters, medical balloons, Nordson is an expert in the design, development and manufacture of complex medical devices and component technologies.


Proprietary single-use plastic connectors, stopcocks, valves, clamps, etc., used for patient care (IV's and blood pressure cuffs), biopharma and gene therapy applications.













## Core Adhesives Innovative Technology

#### Auto-fill Tankless Technology

Adhesive fill systems monitor and maintain optimum adhesive levels

# Variable Dispense Technology

Delivering different add-on rates with one applicator

# Foaming Technology

Maintains bond strength while reducing volume of adhesive required

# Jetting Technology

Dispenses adhesive using non-contact jetting into channels as small as 0.3mm or 300 micron per second

# Precision dispense technology

Increases production efficiency for nonwovens manufacturing process



## Appendix 2:

# Financial Exhibits

#### **Appendix**

#### Non-GAAP Definitions

This presentation contains references to non-GAAP financial information. Although these are non-GAAP measures, we believe that they are useful to an investor in evaluating the company performance for the period presented. These non-GAAP definitions include:

- EBITDA is defined as operating profit plus certain adjustments, such as severance, fees and non-cash inventory charges associated with acquisitions, plus depreciation and amortization.
- Return on Invested Capital is defined as adjusted operating profit after tax as a percentage of the sum of average debt (net of cash)
  plus average shareholders' equity.
- Organic sales defined as sales growth excluding the impacts of changes in foreign currencies and acquisitions. We express period
  over period revenue variances as a percentage.
- Free cash flow is defined as cash flow provided by operating activities less additions to property, plant and equipment.
- Net debt is defined as total long-term debt less cash and cash equivalents.

Amounts may be rounded.

See the company's earnings release for the fourth quarter and full-year ended January 31, 2025, for a reconciliation of the non-GAAP measures Adjusted Operating Profit and EBITDA.





#### Net Income to Adjusted EBITDA (Dollars in thousands)

#### NORDSON CORPORATION

RECONCILIATION OF NON-GAAP MEASURES - NET INCOME TO EBITDA (Unaudited)
(Dollars in thousands)

		Three Months Ended			
	Ja	January 31, 2025		January 31, 2024	
Net income	\$	94,652	\$	109,572	
Income taxes		22,203		29,127	
Interest expense - net		25,618		20,398	
Other income (expense) - net		(1,526)		338	
Depreciation and amortization		37,030		33,544	
Inventory step-up amortization (1)		3,135		2,944	
Severance and other		5,961		_	
Acquisition-related costs (1)		1,030		597	
EBITDA (non-GAAP) (2)	\$	188,103	\$	196,520	

<sup>(1)</sup> Represents fees, severance and non-cash inventory charges associated with acquisitions.

<sup>(2)</sup> EBITDA is a non-GAAP measure used by management to evaluate the Company's ongoing operations. EBITDA is defined as operating profit plus certain adjustments, such as severance, fees and non-cash inventory charges associated with acquisitions, plus depreciation and amortization.



#### Adjusted Operating Profit and EBITDA (Dollars in thousands)

#### NORDSON CORPORATION

RECONCILIATION OF NON-GAAP MEASURES - EBITDA (Unaudited)
(Dollars in thousands)

	Three Months Ended		
	January 31, 2025	January 31, 2024	
SALES BY SEGMENT			
Industrial Precision Solutions	\$ 300,448	\$ 337,742	
Medical and Fluid Solutions	193,609	159,526	
Advanced Technology Solutions	121,363	135,925	
Total sales	\$ 615,420	\$ 633,193	
OPERATING PROFIT			
Industrial Precision Solutions	\$ 95,712	\$ 109,098	
Medical and Fluid Solutions	40,936	46,100	
Advanced Technology Solutions	18,123	18,304	
Corporate	(13,824)	(14,067)	
Total operating profit	\$ 140,947	\$ 159,435	
OPERATING PROFIT ADJUSTMENTS (1)			
Industrial Precision Solutions	\$ 4,611	\$ 3,541	
Medical and Fluid Solutions	5,255	_	
Corporate	260		
Total adjustments	\$ 10,126	\$ 3,541	
DEPRECIATION & AMORTIZATION			
Industrial Precision Solutions	\$ 12,453	\$ 12,920	
Medical and Fluid Solutions	18,141	13,705	
Advanced Technology Solutions	4,648	4,901	
Corporate	1,788	2,018	
Total depreciation & amortization	\$ 37,030	\$ 33,544	
EBITDA (NON-GAAP) (2)			
Industrial Precision Solutions	\$ 112,776 38%	\$ 125,559 37%	
Medical and Fluid Solutions	64,332 33%	59,805 37%	
Advanced Technology Solutions	22,771 19%	23,205 17%	
Corporate	(11,776)	(12,049)	
Total EBITDA	\$ 188,103 31%	\$ 196,520 31%	

<sup>(1)</sup> Represents severance as well as fees and non-cash inventory charges associated with acquisitions.

<sup>(2)</sup> EBITDA is a non-GAAP measure used by management to evaluate the Company's ongoing operations. EBITDA is defined as operating profit plus certain adjustments, such as severance, fees and non-cash inventory charges associated with acquisitions, plus depreciation and amortization.



Profitability (Dollars in thousands)

#### NORDSON CORPORATION

RECONCILIATION OF NON-GAAP MEASURES - ADJUSTED NET INCOME AND EARNINGS PER SHARE
(Unaudited)
(Dollars in thousands)

	Three Months Ended			
	January 31, 2025		January 31, 2024	
GAAP AS REPORTED				
Operating profit	\$	140,947	\$	159,435
Other / interest expense - net		(24,092)		(20,736)
Net income		94,652		109,572
Diluted earnings per share	\$	1.65	\$	1.90
Shares outstanding - diluted		57,486		57,555
OPERATING PROFIT ADJUSTMENTS				
Inventory step-up amortization	\$	3,135	\$	2,944
Acquisition costs		1,030		597
Severance and other		5,961		_
ACQUISITION AMORTIZATION OF INTANGIBLES	\$	19,311	\$	19,387
INTEREST				
Total adjustments	\$	29,437	\$	22,928
Adjustments net of tax	\$	23,844	\$	18,113
EPS effect of adjustments and other discrete tax items	\$	0.41	\$	0.31
NON-GAAP MEASURES-ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE				
Adjusted Net income (1)	S	118,496	\$	127,685
Adjusted Diluted earnings per share (2)	\$	2.06	\$	2.21

<sup>(1)</sup> Adjusted net income is a non-GAAP measure defined as net income plus tax effected adjustments and other discrete tax items

<sup>(2)</sup> Adjusted earnings per share is a non-GAAP measure defined as GAAP EPS adjusted for tax effected adjustments and other discrete tax items.



#### Operating Cash Flow to Free Cash Flow

#### NORDSON CORPORATION

RECONCILIATION OF NON-GAAP MEASURES - OPERATING CASH FLOW TO FREE CASH FLOW (Unaudited)
(Dollars in thousands)

	Year to Date
	January 31, 2025
Net cash provided by operating activities	\$ 159,122
Additions to property, plant and equipment	(21,399)
Free Cash Flow - Year to Date (1)	137,723
Net Income - Year to Date	\$ 94,652
Free Cash Flow Conversion (2)	146 %
	Year to Date
	January 31, 2024
Net cash provided by operating activities	\$ 172,356
Additions to property, plant and equipment	(7,530)
Free Cash Flow - Year to Date (1)	164,826

<sup>(1)</sup> Free Cash Flow - Year to Date is a non-GAAP measure used by management to evaluate the Company's ongoing operations and is defined as Net cash provided by operating activities minus Additions to property, plant and equipment.

<sup>(2)</sup> Free Cash Flow Conversion - Year to Date is a non-GAAP measure used by management to evaluate the Company's ongoing operations and is defined as Free Cash Flow - Year to Date divided by Net Income - Year to Date.